Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic reports positive trial data for MiniMed insulin pumps

Medtronic reports positive trial data for MiniMed insulin pumps

8th July 2014

Medtronic has announced the publication of positive findings from its OpT2mise trial, which illustrates the benefits type 2 diabetes patients can receive from treatment with MiniMed insulin pumps.

Results published in the Lancet have revealed that patients receiving insulin pump therapy can safely achieve better glucose control than multiple daily injections can provide.

This improvement was achieved without any episodes of severe hypoglycemia or associated weight gain impact, while those in the insulin pump group were also able to lower their total daily dose of insulin by more than 20 percent.

While the benefits of insulin pump therapy for people with type 1 diabetes are well-established, this is the largest global study to examine this technique in patients with the type 2 version of the disease.

Dr Francine Kaufman, chief medical officer and vice-president of global, clinical and medical affairs for Medtronic Diabetes, said: "OpT2mise is the latest example of this clinical leadership and a trial that has the potential to help improve access to insulin pump therapy for the many people with type 2 diabetes who could benefit."

This comes after the firm announced last month that it will be allying with Sanofi on new research into innovative treatment strategies for diabetes patients.ADNFCR-8000103-ID-801734058-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.